Collegium Pharmaceutical's (NASDAQ:COLL) investors will be pleased with their favorable 71% return over the last five years
The main point of investing for the long term is to make money. Better yet, you'd like to see the share price move up...
| Ticker |
COLL
|
| CIK | 0001267565 |
| SIC | 2834 |
| Sector | Manufacturing |
| Industry Category | Pharmaceutical Products |
| Industry Group | Pharmaceutical Preparations |
| Address | 100 TECHNOLOGY CENTER DRIVE, STOUGHTON, MA, 02072 |
| Website | collegiumpharma.com |
| Phone | 781-713-3699 |
| CEO | Joseph J. Ciaffoni |
| Employees | 210 |
Our team will help you customize a package that meets the needs of your business.
Request a Consultation|
Standardized FinancialsdocsIntrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals. For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards. Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics: |
|||||||||||||||||||||
|
Income Statement
|
Balance Sheet
|
||||||||||||||||||||
|
Cash Flow Statement
|
Calculations
|
||||||||||||||||||||
|
Latest NewsdocsIntrinio provides up-to-date news articles on every US company from various sources. Here are several examples: |
Collegium Pharmaceutical's (NASDAQ:COLL) investors will be pleased with their favorable 71% return over the last five yearsThe main point of investing for the long term is to make money. Better yet, you'd like to see the share price move up... 5 Insightful Analyst Questions From Collegium Pharmaceutical’s Q1 Earnings CallCollegium Pharmaceutical’s first quarter results were well received by the market, with management crediting growth in its ADHD medicine Jornay and stability in its pain portfolio as the primary drivers. CEO Vikram Karnani highlighted that Jornay prescriptions grew 24% year-over-year, and all three pain medicines delivered single-digit revenue growth, despite typical first-quarter headwinds. Karnani emphasized, “We have made significant progress on each of our strategic priorities,” citing the s 1 Russell 2000 Stock on Our Watchlist and 2 to Keep Off Your RadarThe Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size also means these businesses often lack the resilience and financial flexibility of large-cap firms, making careful selection crucial. COLL Q1 Earnings Call: ADHD Portfolio Drives Growth, Management Details Capital Deployment PrioritiesPharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) reported Q1 CY2025 results topping the market’s revenue expectations, with sales up 22.7% year on year to $177.8 million. The company expects the full year’s revenue to be around $742.5 million, close to analysts’ estimates. Its non-GAAP profit of $1.49 per share was 2.8% above analysts’ consensus estimates. 3 of Wall Street’s Favorite Stocks with Mounting ChallengesWall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts. |